Roche Venture Fund and Amgen will invest in the stem cell-transplant technology developer through a reverse merger transaction which will give it a $490m market capitalisation.

The Sanofi, Amgen, Alphabet, Novartis and PPD-backed clinical trials software producer is joining forces with publicly listed LifeSci Acquisition II Corp.

The Fosun-backed gene therapy developer had set terms for an offering set to raise between $135m and $149m on the Nasdaq Global Select Market.

Hanaco and PayPal are set to exit Divvy, a provider of corporate spend management software, at a 56% premium to the valuation at which they invested in January.

The Takeda and Access Industries-backed oncology therapeutics developer is targeting an offering on the Nasdaq Global Market having previously raised $190m.

Tekfen Ventures, Cisco Investments and Qualcomm Ventures are set to exit the crop monitoring technology developer later this year in a deal with Valmont Industries.

The SK Telecom-backed app advertising and monetisation service provider is set to be bought by Zynga following $21m of venture funding.

The Chernin Group is set to exit the sports betting news platform provider it extablished four years ago, in a $240m acquisition deal.

Bitmain and DRW subsidiary Cumberland Mining are set to exit the crypto finance software provider five years after their investment.

Talaris has raised $150m in an initial public offering almost two decades after being spun out of University of Louisville as Regenerx.